Catalyst
Monitor the outcomes of Part 1 for safety and PK data, which will inform dosing in Part 2, as well as any regulatory implications that arise from the study results.
Humanexa recommends Monitor.
Date
July 2, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.